Publication | Closed Access

11 IMPACT OF IL28B GENOTYPE AND PRETREATMENT SERUM IP-10 IN TREATMENT-NAIVE GENOTYPE-1 HCV PATIENTS TREATED WITH TMC435 IN COMBINATION WITH PEGINTERFERONa-2A AND RIBAVIRIN IN PILLAR STUDY

Viral HepatitisImmunodeficienciesImmunologyAntiviral TherapyHepatitisAntiviral ResponseImmune SystemChronic Viral InfectionAntiviral DrugImmunotherapyMedicineViral Immunity